. 2014 Mar 20;8(2):198–215. doi: 10.1007/s12072-014-9523-y

Table 3.

Summary of primary endpoints including survival rates and rejection rates in this study

First author	Average follow-up period	Follow-up completeness (%)	Group	No. of patients (n)	Patient survival (n)				Graft survival (n)				Acute rejection (n)	Chronic rejection (n)
First author	Average follow-up period	Follow-up completeness (%)	Group	No. of patients (n)	1 year	2 year	3 year	5 year	1 year	2 year	3 year	5 year	Acute rejection (n)	Chronic rejection (n)
Comparison of Tac-based regimen with steroid or not (Sect. I)
Langrehr [25]	425 days	100	Tac + steroid	15	14	14							7
Langrehr [25]	425 days	100	Tac + MMF	15	14	14							4
Pelletier [26]	412 days	100	Tac + MMF + steroid	36	32				32				5
Pelletier [26]	412 days	100	Tac + MMF	36	30				29				9
Margarit al. [27]		100	Tac + steroid	32	27		25	23	24		19	19	10	0
Margarit al. [27]		100	Tac	28	24		23	18	24		23	18	11	0
Reggiani al. [17]	31 months	100	Tac + MMF + steroid	18		18				15			3
Reggiani al. [17]	31 months	100	Tac + MMF	12		11				11			9
Junge [28]	67 months	100	Tac + steroid	14		13							6	1
Junge [28]	67 months	100	Tac + MMF	16		16							6	0
Chen [9]		100	Tac + MMF + steroid	26	12								3
Chen [9]		100	Tac + MMF	28	18								4
Vivarelli [29]	841 days	100	Tac + steroid	16		12							4
Vivarelli [29]	841 days	100	Tac	23		18							2
Manousou [30]	53.5 months	100	Azathioprine + steroid + Tac	49				43					31
Manousou [30]	53.5 months	100	Tac	54				45					22
Weiler [31]		100	Tac + steroid	54	48	46	44	43	44	43	42	39	14	0
Weiler [31]		100	Tac	56	48	44	43	39	47	41	40	36	19	16
Comparison of Tac-based regimen with induction agents or not (Sect. II)
Eason [32]	18.5 months	100	Tac + MMF + steroid	59	50	49			47				18
Eason [32]	18.5 months	100	RATG + Tac + MMF	60	51	49			49				15
Boillot [33]		100	Tac + steroid	347									92
Boillot [33]		100	Daclizumab + Tac	351									89
Spada [34]		100	Tac + steroid	36	33	33			31	31			11
Spada [34]		100	Basiliximab + Tac	36	32	32			29	29			4
Humar [35]	24 months	100	Tac + MMF + steroid	83	67				67				10
Humar [35]	24 months	100	Basiliximab + Tac + MMF	83	73				71				9
Kato [36]		100	Tac/MMF + steroid	39	31				31				17
Kato [36]		100	Daclizumab + Tac/MMF	31	23				21				10
Gras [37]		100	Tac + steroid	34			31				30
Gras [37]		100	Basiliximab + Tac	50			48				47
Foroncewicz [18]	6 years	100	Tac + steroid	18									4
Foroncewicz [18]	6 years	100	Daclizumab + Tac	7									1
Klintmalm [38]	20.9 months	100	Tac + MMF + steroid	72		58				57			7
Klintmalm [38]	20.9 months	100	Daclizumab + Tac + MMF	146		126				124			17

MMF mycophenolate mofetil, RATG rabbit antithymocyte globulin, Tac tacrolimus